Direct-to-patient is more than just telehealth – with EVERSANA’s Faruk Abdullah

The idea of direct-to-patient channels in pharma conjures up services like Lilly Direct and PfizerForAll. But direct-to-patient is more than telehealth and digital marketing – it’s a combination of these offerings stitched together in a comprehensive and patient-friendly way.

At Reuters Pharma USA in Philadelphia, pharmaphorum editor-in-chief Jonah Comstock spoke with Faruk Abdullah, chief business officer at EVERSANA (pharmaphorum’s parent company), about how EVERSANA thinks about direct-to-patient.

Fresh off a panel on the topic, Abdullah discusses why direct-to-patient is a win for equity and access, why providers shouldn’t fear pharma going direct-to-patient (and what their role is in the new pharma-patient relationship), and some of the advantages direct-to-patient channels offer around medication adherence.

Check out the video.